JP2010047616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010047616A5 JP2010047616A5 JP2009274999A JP2009274999A JP2010047616A5 JP 2010047616 A5 JP2010047616 A5 JP 2010047616A5 JP 2009274999 A JP2009274999 A JP 2009274999A JP 2009274999 A JP2009274999 A JP 2009274999A JP 2010047616 A5 JP2010047616 A5 JP 2010047616A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- subject
- alzheimer
- coa reductase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/046,235 US6080778A (en) | 1998-03-23 | 1998-03-23 | Methods for decreasing beta amyloid protein |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537538A Division JP2002507564A (ja) | 1998-03-23 | 1999-03-23 | βアミロイドタンパク質を減少させるための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010047616A JP2010047616A (ja) | 2010-03-04 |
| JP2010047616A5 true JP2010047616A5 (enExample) | 2010-10-14 |
Family
ID=21942345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537538A Pending JP2002507564A (ja) | 1998-03-23 | 1999-03-23 | βアミロイドタンパク質を減少させるための方法 |
| JP2009274999A Pending JP2010047616A (ja) | 1998-03-23 | 2009-12-02 | βアミロイドタンパク質を減少させるための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000537538A Pending JP2002507564A (ja) | 1998-03-23 | 1999-03-23 | βアミロイドタンパク質を減少させるための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US6080778A (enExample) |
| EP (1) | EP1063980A2 (enExample) |
| JP (2) | JP2002507564A (enExample) |
| AU (1) | AU759257B2 (enExample) |
| CA (1) | CA2324999A1 (enExample) |
| WO (1) | WO1999048488A2 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072138A1 (en) * | 1997-11-25 | 2004-04-15 | Medical University Of South Carolina | Attenuation of ischemia/reperfusion injury |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US20080275104A1 (en) * | 1997-11-25 | 2008-11-06 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| US8679534B2 (en) * | 1997-12-12 | 2014-03-25 | Andrx Labs, Llc | HMG-CoA reductase inhibitor extended release formulation |
| US20020188012A1 (en) * | 1998-01-28 | 2002-12-12 | Bisgaier Charles Larry | Method for treating Alzheimer's disease |
| US6472421B1 (en) * | 1998-11-13 | 2002-10-29 | Nymox Corporation | Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor |
| US6428950B1 (en) * | 1998-11-25 | 2002-08-06 | Scios Inc. | Assay to identify compounds that alter apolipoprotein E expression |
| US20020055529A1 (en) * | 1998-12-02 | 2002-05-09 | Bisgaier Charles Larry | Method for treating alzheimer's disease |
| US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
| WO2001032161A2 (en) * | 1999-11-04 | 2001-05-10 | Andrx Corporation | Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders |
| AR027878A1 (es) * | 1999-11-05 | 2003-04-16 | Wyeth Corp | Metodos para identificar y utilizar compuestos inhibidores de amiloides |
| US20010028895A1 (en) * | 2000-02-04 | 2001-10-11 | Bisgaier Charles L. | Methods of treating alzheimer's disease |
| US7439052B2 (en) * | 2000-06-29 | 2008-10-21 | Lipid Sciences | Method of making modified immunodeficiency virus particles |
| US7407663B2 (en) | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified immunodeficiency virus particles |
| US7407662B2 (en) * | 2000-06-29 | 2008-08-05 | Lipid Sciences, Inc. | Modified viral particles with immunogenic properties and reduced lipid content |
| US20090017069A1 (en) * | 2000-06-29 | 2009-01-15 | Lipid Sciences, Inc. | SARS Vaccine Compositions and Methods of Making and Using Them |
| AUPQ846900A0 (en) * | 2000-06-29 | 2000-07-27 | Aruba International Pty Ltd | A vaccine |
| US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| WO2002062824A2 (en) * | 2001-02-05 | 2002-08-15 | Andrx Corporation | Method of treating amyloid ? precursor disorder |
| EP1370210A4 (en) * | 2001-02-07 | 2004-08-18 | Mclean Hospital Corp | HYPOCHOLESTEROLEMIANTS USED TO TREAT PSYCHOLOGICAL AND COGNITIVE DISORDERS |
| US20030191144A1 (en) * | 2001-06-12 | 2003-10-09 | Active Pass Pharmaceuticals, Inc. | Compounds, compositions and methods for modulating beta-amyloid production |
| JP2005501817A (ja) * | 2001-06-12 | 2005-01-20 | アクティブ パス ファーマシューティカルズ， インコーポレイテッド | β−アミロイド産生を調節する化合物、組成物および方法 |
| US20030127386A1 (en) * | 2001-06-25 | 2003-07-10 | Bomberger David C. | Hollow fiber contactor systems for removal of lipids from fluids |
| CA2451633C (en) * | 2001-06-25 | 2010-11-30 | Lipid Sciences, Inc. | Systems and methods using a solvent for the removal of lipids from fluids |
| AU2002322284A1 (en) * | 2001-06-25 | 2003-01-08 | Lipid Sciences, Inc. | Systems and methods using multiple solvents for the removal of lipids from fluids |
| US6991727B2 (en) * | 2001-06-25 | 2006-01-31 | Lipid Sciences, Inc. | Hollow fiber contactor systems for removal of lipids from fluids |
| US20060060520A1 (en) * | 2001-06-25 | 2006-03-23 | Bomberger David C | Systems and methods using a solvent for the removal of lipids from fluids |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| CA2478184A1 (en) * | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Drug combination therapy |
| US20050222122A1 (en) * | 2002-04-02 | 2005-10-06 | Sean Lilienfeld | Statin therapy for enhancing cognitive maintenance |
| JP2005533851A (ja) * | 2002-07-19 | 2005-11-10 | アリックス セラピューティクス、インコーポレイテッド | 高コレステロール血症処置用物質および方法 |
| EP1534243A4 (en) * | 2002-08-26 | 2008-08-13 | Lipid Sciences Inc | TREATMENT OF ALZHEIMER WITH ENTLIPIDED PROTEIN PARTICLES |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| FR2848452B1 (fr) * | 2002-12-12 | 2007-04-06 | Aventis Pharma Sa | Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CN1756756A (zh) * | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CA2517573C (en) * | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| ATE534381T1 (de) * | 2003-03-17 | 2011-12-15 | Japan Tobacco Inc | Pharmazeutische cetp-inhibitor-zusammensetzungen |
| JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法 |
| TWI393560B (zh) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| US7393826B2 (en) | 2003-07-03 | 2008-07-01 | Lipid Sciences, Inc. | Methods and apparatus for creating particle derivatives of HDL with reduced lipid content |
| PT1641421T (pt) * | 2003-07-03 | 2019-03-27 | Hdl Therapeutics Inc | Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido |
| CN1870984A (zh) * | 2003-10-22 | 2006-11-29 | 莫茨药物股份两合公司 | 1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途 |
| US6960803B2 (en) * | 2003-10-23 | 2005-11-01 | Silicon Storage Technology, Inc. | Landing pad for use as a contact to a conductive spacer |
| EP1711197A4 (en) * | 2003-12-23 | 2008-11-05 | Musc Found For Res Dev | METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS |
| US20070161700A1 (en) * | 2004-12-28 | 2007-07-12 | Kowa Company, Ltd. | Inhibitor for the formation of y-secretase complex |
| US20070166360A1 (en) * | 2004-03-31 | 2007-07-19 | Kowa Co., Ltd. | External preparation |
| WO2005123955A2 (en) * | 2004-06-09 | 2005-12-29 | Children's Medical Center Corporation | Methods and compositions for modifying gene regulation and dna damage in ageing |
| US20060039890A1 (en) * | 2004-08-20 | 2006-02-23 | Renshaw Perry F | Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant |
| US8353184B2 (en) * | 2005-01-21 | 2013-01-15 | Sinox Company Ltd. | Tamper indicating padlock |
| CA2609980C (en) * | 2005-05-27 | 2015-10-13 | Queen's University At Kingston | Treatment of protein folding disorders |
| WO2007112288A2 (en) * | 2006-03-23 | 2007-10-04 | Mount Sinai School Of Medicine | Cardiovascular composition and use the same for the treatment of alzheimers disease |
| US20080227846A1 (en) * | 2007-03-13 | 2008-09-18 | Musc Foundation For Research Development | Methods of treating juvenile type 1 diabetes mellitus |
| TWI432195B (zh) * | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| ES2330184B1 (es) * | 2008-06-03 | 2010-07-05 | Neuron Biopharma, S.A. | Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores. |
| WO2010086864A1 (en) | 2009-02-02 | 2010-08-05 | Galmed International Ltd. | Methods and compositions for treating alzheimer's disease |
| KR102287877B1 (ko) * | 2014-03-13 | 2021-08-11 | 주식회사 하이폭시 | 차전자피를 포함하는 기억력 및 인지기능 증진용 조성물 |
| US20200199645A1 (en) * | 2017-09-08 | 2020-06-25 | Control Of Innate Immunity Technology Research Association | Device and method for diagnosis of alzheimer's symptoms |
| CN118594035A (zh) | 2017-11-22 | 2024-09-06 | Hdl治疗公司 | 用于对血浆处理系统的流体回路进行灌注的系统和方法 |
| CA3087207A1 (en) | 2017-12-28 | 2019-07-04 | Hdl Therapeutics, Inc. | Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692895A (en) * | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US5252471A (en) * | 1992-03-09 | 1993-10-12 | Merck & Co., Inc. | Directed biosynthesis of cholesterol lowering compounds |
| AU7397094A (en) * | 1993-08-30 | 1995-03-22 | Merck & Co., Inc. | Prevention and treatment of alzheimer's disease |
| AU2401697A (en) * | 1996-06-20 | 1998-01-07 | Pfizer Inc. | 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors |
| US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
| DE19716120A1 (de) * | 1997-04-17 | 1998-10-22 | Europ Lab Molekularbiolog | Verwendung von cholesterinsenkenden Mitteln |
| US5929062A (en) * | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
| CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| CA2311356C (en) * | 1998-01-28 | 2004-07-13 | Warner-Lambert Company | Method for treating alzheimer's disease |
-
1998
- 1998-03-23 US US09/046,235 patent/US6080778A/en not_active Expired - Lifetime
-
1999
- 1999-01-28 US US09/239,387 patent/US6440387B1/en not_active Expired - Fee Related
- 1999-03-23 CA CA002324999A patent/CA2324999A1/en not_active Abandoned
- 1999-03-23 WO PCT/US1999/006396 patent/WO1999048488A2/en not_active Ceased
- 1999-03-23 JP JP2000537538A patent/JP2002507564A/ja active Pending
- 1999-03-23 AU AU32009/99A patent/AU759257B2/en not_active Ceased
- 1999-03-23 EP EP99914084A patent/EP1063980A2/en not_active Withdrawn
-
2002
- 2002-02-28 US US10/086,398 patent/US20020120003A1/en not_active Abandoned
- 2002-07-14 US US10/198,331 patent/US20020183379A1/en not_active Abandoned
-
2005
- 2005-09-22 US US11/232,844 patent/US20060025469A1/en not_active Abandoned
-
2009
- 2009-12-02 JP JP2009274999A patent/JP2010047616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010047616A5 (enExample) | ||
| RU2022100434A (ru) | Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения | |
| JP2022116083A5 (enExample) | ||
| EP2322221A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF CANCER | |
| JP2010528011A5 (enExample) | ||
| CR11736A (es) | Cápsula para la prevención de enfermedades cardiovasculares | |
| WO2008045170A3 (en) | Statin and omega-3 fatty acids for reduction of apo-b levels | |
| BR112012006692B8 (pt) | composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato | |
| JP2008509132A5 (enExample) | ||
| EP2415763A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA | |
| NZ595116A (en) | Use of rosuvastatin lactols as medicaments | |
| UA98466C2 (uk) | КОМБІНАЦІЯ ІНГІБІТОРА HMG-CоA-РЕДУКТАЗИ Й ІНГІБІТОРА ФОСФОДІЕСТЕРАЗИ 4, ПРИЗНАЧЕНА ДЛЯ ЛІКУВАННЯ ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ ЛЕГЕНІВ | |
| JP2009537554A5 (enExample) | ||
| JP2006512361A5 (enExample) | ||
| EP1865955A4 (en) | METHOD FOR TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND ALPHA REDUCTASE INHIBITORS | |
| JP2008063322A5 (enExample) | ||
| GB0816269D0 (en) | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease | |
| EP2716285A3 (en) | New method for identifying compounds useful for treating and/or preventing diseases associated with bone loss | |
| JP2013536408A5 (enExample) | ||
| JP2014521738A5 (enExample) | ||
| EP2392337A3 (en) | Use of 24-norUDCA | |
| AR080023A1 (es) | Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa | |
| JP2008513379A5 (enExample) | ||
| ES2422877B1 (es) | Combinación y composición para el tratamiento de obesidad | |
| WO2009151295A3 (ko) | 아젤니디핀과 ＨＭＧ－ＣｏＡ 환원효소 억제제 또는 안지오텐신 Ⅱ 수용체 차단제를 포함하는 약제학적 제제 |